Autopsy report · NCT03224923

A Novel Strategy For Personalized Long-Term Dual Antiplatelet Therapy (RAPID EXTEND PILOT STUDY)

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Competing study to be started in November 2018”

The sponsor’s own words in the registry.

Life of this trial

Registered 1 month before it started.
Ran for about 1 year 1 month before it stopped.
5 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 4
Sponsor: Ottawa Heart Institute Research Corporation
Sponsor type: University, hospital or other
Conditions: Stable Coronary Syndrome; Percutaneous Coronary Intervention; Antiplatelet Therapy; Ticagrelor
Interventions: Ticagrelor 60mg; Clopidogrel 75mg; Aspirin 81 mg
Participants: 5
Sites: 1
Countries: Canada

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.